Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Magnesium Diasporal

PreclinicalSmall molecule

SSwiss Cancer Institute

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic NSCLC - Non-Small Cell Lung CancerRecruiting

Metastatic NSCLC - Non-Small Cell Lung CancerPreclinical

Recruiting

Timeline

Expected Milestones

Q1 2035

PreclinicalRecruiting

Metastatic NSCLC - Non-Small Cell Lung Cancer

NCT07149649

Clinical

Trials by Indication[1]

Metastatic NSCLC - Non-Small Cell Lung Cancer1 trial

Magnesium Supplementation in Addition to Standard Chemo-immunotherapy in Patients With Locally Advanced Unresectable Stage III or Metastatic Stage IV Non-small Cell Lung Cancer (NSCLC). A Double-blind Randomized Multicenter Phase II/III Study.

Recruiting·SSwiss Cancer Institute·Preclinical·NCT07149649·230 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Magnesium Diasporal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Magnesium Diasporal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Magnesium Diasporal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Swiss Cancer Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSwiss Cancer Institute

Related News